PATENT CLAIM ANALYSIS

Application Number: 15993267
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-12
Patent Classification: ["514", "04400A"]

Abstract:
Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.

Claim (Index 9):
A pharmaceutical composition, comprising an antisense oligomer of  claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 93.0
- Lexical Diversity: 1.05
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13219401', '14240832', '15339069', '14368307', '15735094']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7678064580622141
- 35 USC 102 Novelty (BERT): 0.5540643924435302
- Combined Prediction Score: 0.7464322515003459
- Mean Citation Score: 384.060624
- Max Citation Score: 422.58295
- Similarity Product: 301.63727200424665

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test